-
Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis.
Liu C,
Batliwalla F,
Li W,
Lee A,
Roubenoff R,
Beckman E,
Khalili H,
Damle A,
Kern M,
Furie R,
Dupuis J,
Plenge RM,
Coenen MJ,
Behrens TW,
Carulli JP,
Gregersen PK.
Biogen Idec Inc., Cambridge, Massachusetts, USA.
The prediction of response (or non-response) to anti-TNF treatment for rheumatoid arthritis (RA) is a pressing clinical problem. We conducted a genome-wide association study using the Illumina HapMap300 SNP chip on 89 RA patients prospectively followed after beginning anti-TNF therapy as part of Autoimmune Biomarkers Collaborative Network (ABCoN [Autoimmune Bio-markers Collaborative Network]) patient cohort. Response to therapy was determined by the change in Disease Activity Score (DAS28) observed after 14 wks. We used a two-part analysis that treated the change in DAS28 as a continuous trait and then incorporated it into a dichotomous trait of "good responder" and "nonresponder" by European League Against Rheumatism (EULAR) criteria. We corrected for multiple tests by permutation, and adjusted for potential population stratification using EIGENSTRAT. Multiple single nucleotide polymorphism (SNP) markers showed significant associations near or within loci including: the v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) gene on chromosome 20; the type I interferon gene IFNk on chromosome 9; and in a locus on chromosome 7 that includes the paraoxonase I (PON1) gene. An SNP in the IL10 promoter (rs1800896) that was previously reported as associated with anti-TNF response was weakly associated with response in this cohort. Replications of these results in independent and larger data sets clearly are required. We provide a reference list of candidate SNPs (P < 0.01) that can be investigated in future pharmacogenomic studies.
PMID: 18615156 [PubMed - indexed for MEDLINE]
PMCID: PMC2443997
-
Cited by 4 PubMed Central articles
-
Genetic susceptibility to psoriasis: an emerging picture.
Smith RL, Warren RB, Griffiths CE, Worthington J.
Genome Med. 2009 Jul 22; 1(7):72. Epub 2009 Jul 22.
[Genome Med. 2009]
-
What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases.
Oliver JE, Silman AJ.
Arthritis Res Ther. 2009; 11(3):223. Epub 2009 May 19.
[Arthritis Res Ther. 2009]
-
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.
Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, Van Vollenhoven RF, Lampa J, Saito K, Tanaka Y, et al.
Arthritis Res Ther. 2009; 11(3):R76. Epub 2009 May 21.
[Arthritis Res Ther. 2009]
- » See all...